CMRX(Delisted)
Chimerix·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 2
Significant Revenue Decline
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CMRX
Chimerix, Inc.
A company that developing oral antiviral therapeutics for the prevention of cytomegalovirus infection
2505 Meridian Parkway
, Suite 100
, Durham
, North Carolina 27713
--
Chimerix, Inc., was incorporated in Delaware in April 2000. Chimerix is a biopharmaceutical company whose mission is to develop drugs that meaningfully improve and prolong the lives of patients facing fatal diseases. The company is focused on developing pyridone as a potential new selective cancer therapy. At present, the most advanced disopyrum is ONC 201, and its main indication is the clinical development stage of H 3 K 27 M mutant glioma. In addition, disopyrone ONC 206 is currently undergoing dose-escalation clinical trials.
Company Financials
EPS
CMRX has released its 2024 Q4 earnings. EPS was reported at -0.25, versus the expected -0.28, beating expectations. The chart below visualizes how CMRX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CMRX has released its 2024 Q4 earnings report, with revenue of 57.00K, reflecting a YoY change of 1325.00%, and net profit of -22.95M, showing a YoY change of -26.39%. The Sankey diagram below clearly presents CMRX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
